Venus Medtech (启明医疗) IPO Trading: Allocation and Buy-Level
Venus Medtech, the dominant player in the heart valve replacement segment in China, raised USD 311 million at HKD 33.0 per share. In this insight,...
635 Views
ECM Weekly (8 Dec 2019) - OneConnect, JS Global, Renrui, Poly Property, Freee, Burger King India
Aequitas Research puts out a weekly update on the deals that have been covered by the team recently along with updates for upcoming IPOs. This...
602 Views
ECM Weekly (1 Dec 2019) - Venus Medtech, Alphamab, CMC REIT, XD, BAM
Aequitas Research puts out a weekly update on the deals that have been covered by the team recently along with updates for upcoming IPOs. It has...
616 Views
Venus Medtech IPO: Fairly Valued and More Room for Share Price to Grow
In our previous insight on Venus Medtech IPO Venus Medtech IPO: First Mover Advantage in Chinese TAVR Market to Support Growth , we discussed the...
640 Views
Venus Medtech IPO: Valuation Tempting at the Low-End
Venus MedTech (2500 HK) is a leading transcatheter heart valve medical device company in China. Venus has launched a Hong Kong IPO to raise up to...
626 Views